This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Intellia Therapeutics’s 8K filing here.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Recommended Stories
- Five stocks we like better than Intellia Therapeutics
- Consumer Discretionary Stocks Explained
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Using the MarketBeat Dividend Yield Calculator
- Applied Materials Market Capitulates: Now is the Time to Buy
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Ultra-High Dividend Yield Stocks for the New Year
